TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group

Research output: Contribution to journalJournal articleResearchpeer-review

Charlotte Levin Tykjær Jørgensen, Christina Annette Bjerre, Bent Laursen Ejlertsen, Karsten D. Bjerre, Eva Balslev, Annette Bartels, Nils Brünner, Dorte L. Nielsen

Original languageEnglish
Article number360
JournalB M C Cancer
Number of pages14
Publication statusPublished - 2014

    Research areas

  • TIMP-1, Gemcitabine, Docetaxel, Breast cancer, Prediction, Prognosis

Number of downloads are based on statistics from Google Scholar and www.ku.dk

No data available

ID: 125791294